CA
NZ
UK
AU
IND
US
…
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -374.03M | -72.81M | -114.32M | -23.36M | -88.42M |
| Minority interest | 15.32M | 0.00M | - | - | - |
| Net income | -358.73M | -72.81M | -114.33M | -23.36M | -88.42M |
| Selling general administrative | 266.88M | 119.02M | 119.64M | 64.89M | 50.58M |
| Gross profit | 15.03M | 39.90M | 31.06M | 27.24M | 27.68M |
| Reconciled depreciation | 4.62M | 4.05M | 4.15M | 3.96M | 3.78M |
| Ebit | -362.57M | -70.84M | -113.25M | -50.63M | -35.84M |
| Ebitda | -357.94M | -66.80M | -109.10M | -46.67M | -32.06M |
| Depreciation and amortization | 4.62M | 4.05M | 4.15M | 3.96M | 3.78M |
| Non operating income net other | - | - | - | 36.88M | - |
| Operating income | -272.30M | -83.40M | -105.43M | -50.63M | -35.84M |
| Other operating expenses | 302.56M | 139.99M | 152.17M | 88.67M | 67.16M |
| Interest expense | 11.46M | 1.96M | 1.07M | 9.60M | 39.76M |
| Tax provision | 0.03M | -0.00M | 0.04M | 0.00M | 0.01M |
| Interest income | - | - | - | - | 0.00M |
| Net interest income | -11.46M | -1.96M | -1.52M | -9.60M | -39.76M |
| Non recurring | - | - | - | - | 0.00M |
| Income tax expense | 0.03M | -0.00M | 0.01M | 0.00M | 0.01M |
| Total revenue | 30.25M | 56.59M | 46.74M | 38.03M | 31.32M |
| Total operating expenses | 287.33M | 123.30M | 136.49M | 77.87M | 63.52M |
| Cost of revenue | 15.22M | 16.69M | 15.68M | 10.80M | 3.63M |
| Total other income expense net | -101.72M | 10.59M | -8.89M | 27.27M | -52.58M |
| Net income from continuing ops | -374.05M | -72.81M | -110.81M | -23.36M | -1.01M |
| Net income applicable to common shares | - | - | - | -23.36M | 0.78M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 364.98M | 92.95M | 101.31M | 86.53M | 77.93M |
| Intangible assets | 59.09M | 32.45M | 36.48M | 40.59M | 38.80M |
| Other current assets | 7.34M | 9.40M | 4.05M | 4.81M | 1.83M |
| Total liab | 576.73M | 285.59M | 274.25M | 50.29M | 301.81M |
| Total stockholder equity | -207.78M | -192.64M | -172.94M | 36.24M | -223.88M |
| Deferred long term liab | - | - | - | 1.23M | 5.19M |
| Other current liab | 305.11M | 170.55M | 98.79M | 35.65M | 107.08M |
| Common stock | 0.00M | 0.02M | 0.02M | 0.01M | 0.02M |
| Capital stock | 0.00M | 0.03M | 0.02M | 0.02M | 0.02M |
| Retained earnings | -921.79M | -563.05M | -490.25M | -375.91M | -352.55M |
| Other liab | - | - | - | 4.78M | 35.70M |
| Good will | 13.48M | 13.48M | 13.48M | 13.48M | 13.48M |
| Other assets | - | - | - | 0.94M | 0.54M |
| Cash | 4.96M | 3.27M | 3.92M | 2.18M | 4.34M |
| Total current liabilities | 483.65M | 259.63M | 250.38M | 44.84M | 169.42M |
| Current deferred revenue | - | 4.12M | 1.45M | - | - |
| Net debt | 127.59M | 34.69M | 124.54M | -0.77M | 150.41M |
| Short term debt | 92.28M | 35.59M | 109.19M | 0.74M | 58.06M |
| Short long term debt | 86.78M | 34.88M | 108.43M | - | 57.56M |
| Short long term debt total | 132.54M | 37.96M | 128.46M | 1.41M | 154.75M |
| Other stockholder equity | 719.81M | 364.07M | 317.29M | 412.14M | 128.65M |
| Property plant equipment | - | - | - | 0.77M | 2.11M |
| Total current assets | 38.36M | 41.55M | 46.78M | 29.61M | 23.00M |
| Long term investments | 128.04M | 2.42M | - | - | - |
| Net tangible assets | - | - | - | -17.84M | 130.68M |
| Short term investments | 6.03M | - | - | - | - |
| Net receivables | 15.24M | 26.44M | 34.60M | 21.24M | 14.27M |
| Long term debt | 22.48M | 0.84M | 17.04M | - | 3.83M |
| Inventory | 4.79M | 2.44M | 4.21M | 1.38M | 2.56M |
| Accounts payable | 86.27M | 52.62M | 40.95M | 8.45M | 4.28M |
| Accumulated other comprehensive income | -5.80M | 6.32M | 0.00M | - | - |
| Common stock total equity | - | - | - | 0.01M | 0.00M |
| Preferred stock total equity | - | - | - | 0.00M | - |
| Retained earnings total equity | - | - | - | -375.91M | -8.70M |
| Non currrent assets other | 224.64M | 0.12M | 0.09M | 0.94M | 0.54M |
| Non current assets total | 326.62M | 51.41M | 54.53M | 56.92M | 54.93M |
| Capital lease obligations | 14.88M | 2.24M | 3.00M | 1.41M | 1.65M |
| Long term debt total | - | - | - | - | 3.83M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -17.04M | -2.67M | -0.16M | -2.07M | 0.00M |
| Change to liabilities | - | - | - | 32.42M | 0.21M |
| Total cashflows from investing activities | 4.08M | -2.67M | -0.33M | -2.07M | -139.38M |
| Net borrowings | 0.44M | -64.21M | 0.73M | 124.26M | 0.34M |
| Total cash from financing activities | -5.46M | -18.13M | 23.58M | 21.17M | 28.16M |
| Change to operating activities | - | - | - | 48.65M | 20.00M |
| Net income | -358.73M | -72.81M | -114.33M | -23.36M | -88.42M |
| Change in cash | 1.68M | -1.46M | 2.54M | -2.15M | -0.50M |
| Begin period cash flow | 3.27M | 4.73M | 2.18M | 4.34M | 4.84M |
| End period cash flow | 4.96M | 3.27M | 4.73M | 2.18M | 4.34M |
| Total cash from operating activities | 3.82M | 19.35M | -20.71M | -21.26M | -28.66M |
| Issuance of capital stock | 0.00M | 44.64M | 35.46M | - | - |
| Depreciation | 4.62M | 4.05M | 4.15M | 3.96M | 3.78M |
| Other cashflows from investing activities | 4.22M | -0.68M | -0.30M | -2.06M | -139.38M |
| Dividends paid | - | - | 10.00M | - | - |
| Change to inventory | 1.80M | 1.46M | -2.84M | 1.18M | -1.42M |
| Change to account receivables | 13.84M | -6.27M | -13.36M | -6.97M | -1.14M |
| Sale purchase of stock | - | 0.00M | -10.00M | 0.10M | 140.31M |
| Other cashflows from financing activities | -30.53M | 1.44M | -2.60M | 124.78M | 110.38M |
| Change to netincome | - | - | - | -31.66M | -1.78M |
| Capital expenditures | 0.13M | 0.60M | 0.33M | 2.07M | 0.01M |
| Change receivables | - | - | - | -6.97M | - |
| Cash flows other operating | - | - | - | 0.04M | -0.02M |
| Cash and cash equivalents changes | - | - | - | -2.15M | 0.48M |
| Change in working capital | 113.97M | 64.84M | 65.80M | 45.67M | 13.60M |
| Stock based compensation | 15.49M | 15.69M | 14.60M | 5.28M | 5.82M |
| Other non cash items | 228.47M | 7.58M | 9.08M | -52.80M | 23.79M |
| Free cash flow | 3.68M | 18.75M | -21.04M | -23.32M | -28.66M |
Sector: Healthcare Industry: Drug Manufacturers - General
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SCLX Scilex Holding Company |
-0.21 10.19% |
1.85 | - | 5.58 | 1.10 | 28.85 | 4.23 | -2.64 |
| LLY Eli Lilly and Company |
43.84 3.19% |
1417.54 | 38.16 | 24.15 | 12.72 | 29.95 | 13.31 | 25.43 |
| JNJ Johnson & Johnson |
-2.00 0.73% |
273.20 | 30.96 | 20.79 | 6.58 | 7.55 | 6.84 | 19.73 |
| ABBV AbbVie Inc |
4.10 1.41% |
294.89 | 74.10 | 16.21 | 7.22 | 50.46 | 8.18 | 27.04 |
| RHHVF Roche Holding AG Participation |
2.65 0.54% |
490.00 | 24.16 | 16.53 | 5.71 | 8.88 | 4.94 | 14.76 |
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California.
960 San Antonio Road, Palo Alto, CA, United States, 94303
650 516 4310
34
| Name | Title | Year Born |
|---|---|---|
| Mr. Jaisim Shah | Pres, CEO & Director | 1960 |
| Mr. Suresh K. Khemani | Sr. VP & Chief Commercial Officer | 1960 |
| Dr. Dmitri V. Lissin M.D. | Sr. VP & Chief Medical Officer | 1959 |
| Dr. Henry H. Ji Ph.D. | Exec. Chairman | 1964 |
| Ms. Elizabeth Adkins Czerepak M.B.A. | Exec. VP, CFO, Chief Bus. Officer & Sec. | 1956 |
| Dr. Suketu D. Desai Ph.D. | Chief Technical Officer & Sr. VP | 1965 |
| Mr. Steven F. Lincoln J.D. | Gen. Counsel & Chief Compliance Officer | NA |
| Dr. Henry H. Ji Ph.D. | Executive Chairman | 1964 |
| Mr. Stephen Ma | Senior VP, CFO & Corporate Secretary | 1973 |
| Mr. Jaisim Shah | President, CEO & Director | 1960 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...